• Amikacin (BAY416651) Resistance Research Workflows

  2026-09-02

  Use Amikacin (BAY416651) as a practical bacterial protein synthesis inhibitor for mapping susceptibility, enzyme-mediated resistance, and plasmid-associated dissemination. This workflow connects phenotypic testing with the carbapenemase transmission patterns reported in carbapenem-resistant Enterobacter cloacae, while highlighting preparation and interpretation controls.

• Gut Microbial H2S Suppresses GLP-1 in Male Mice

  2026-09-02

  A 2024 Nature Metabolism study identifies Desulfovibrio-derived hydrogen sulfide as a gut-localized metabolic stressor that suppresses GLP-1 production in male mice. By connecting microbial dysbiosis to mitochondrial respiration, the unfolded protein response, and enteroendocrine L-cell function, the work provides a mechanistic framework for how intestinal metabolites can impair host metabolism without requiring extensive systemic circulation.

• Shrimp STING Reveals an IFN-Like Antiviral Axis

  2026-09-01

  The reference study shows that Litopenaeus vannamei STING can bind both cytosolic double-stranded DNA and cyclic dinucleotides, extending STING function beyond its traditionally emphasized role as a downstream CDN adaptor. In vivo, this activity connects viral nucleic-acid sensing to an IKKε–IRF–Vago4 pathway, providing evidence for an ancestral DNA-sensing antiviral circuit in an arthropod.

• 1-methyl Adenosine: From Signal to Strategy

  2026-09-01

  1-methyl Adenosine is moving from an RNA-derived metabolite to a strategically useful translational readout. This article connects its tRNA-processing biology, quantitative UHPLC–MS/MS measurement, cancer metabolism studies, biomarker discovery, and therapeutic target validation while outlining practical assay and interpretation safeguards.

• Chloramphenicol for Plasmid Selection

  2026-08-31

  Chloramphenicol provides a practical selection handle for plasmid maintenance, cloning, and controlled plasmid-loss experiments. This guide translates its ribosome-targeting activity into reproducible workflows and connects plasmid selection design with recent evidence on carbapenemase-gene mobility in Enterobacter cloacae.

• Ampicillin Sodium: Mechanism to Translation

  2026-08-30

  A thought-leadership guide to using Ampicillin sodium as a mechanistically grounded benchmark across antibacterial activity assays, recombinant protein workflows, bacterial infection models, and antibiotic resistance research.

• OCT2 and MATE1 Inhibition by Antiemetic Drugs

  2026-08-29

  George and colleagues systematically compared five 5-HT3 receptor antagonists for inhibition of renal OCT2- and MATE1-mediated transport using complementary cellular models. The results identify substantial drug-specific differences, including potent OCT2 inhibition by palonosetron and particularly strong MATE1 inhibition by ondansetron, providing a mechanistic basis for evaluating renal transporter interactions during antiemetic therapy.

• A-1331852: BCL-XL Inhibitor Workflow

  2026-08-29

  A-1331852 provides a selective way to test BCL-XL dependence, distinguish apoptosis from nonspecific cytotoxicity, and investigate residual chemotherapy-induced senescent cells. This practical workflow combines concentration-response design, orthogonal death readouts, genetic controls, and troubleshooting for more interpretable cancer research data.

• FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Inflammation

  2026-08-28

  The reference study identifies a FLOT1–FOSL2–EphA2 regulatory axis that drives pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 mouse model. Its combined molecular, histological, and behavioral evidence links this pathway to neuroinflammation and spatial-memory impairment, while also defining testable intervention points for neurodegenerative disease research.

• Concanamycin A: Reliable V-ATPase Assays

  2026-08-28

  A scenario-based guide to using Concanamycin A (SKU A8633) in cell viability, proliferation, cytotoxicity, apoptosis, and invasion workflows. It explains formulation, exposure design, controls, data interpretation, and practical vendor-selection criteria for reproducible cancer biology research.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-08-27

  The reference study evaluates lapatinib and Telatinib (BAY 57-9352) as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is linking treatment to reduced proliferation, invadopodia formation, and endothelial tube formation, while also highlighting the need for stronger target-engagement and synergy studies.

• Cyanine 3 Tyramide for Neural Signal Amplification

  2026-08-27

  Cyanine 3 Tyramide converts weak HRP-linked signals into localized orange fluorescence for challenging brain-tissue assays. This guide translates findings on early life adversity and oxytocin signaling into practical IHC, ISH, multiplex imaging, and fixed-cell flow cytometry workflows.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-26

  This 2023 study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, renal fibrosis, and inflammation. By testing AZ505 and LLY-507 in an animal model and tubular epithelial cells, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, extracellular-matrix accumulation, inflammatory signaling, and Smad3/STAT3 activation.

• Small-Molecule Antagonists of Shh–Heparin Binding

  2026-08-26

  Lamson and colleagues screened 34,560 compounds to identify small molecules that disrupt Sonic hedgehog N-terminal fragment binding to heparin, uncovering 26 confirmed antagonists and multiple active scaffolds. Cell-based, transcriptional, thermal-shift, and docking experiments showed that selected compounds inhibit ligand-level Hedgehog signaling rather than bypassing the pathway through Smoothened.

• TCAIM Control of OGDH and Mitochondrial Metabolism

  2026-08-25

  The reference study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This finding expands the role of mitochondrial proteostasis from protein folding to direct control of metabolic enzyme abundance, with consequences for OGDH complex activity and carbohydrate catabolism.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page